Photo taken from Dana-Farber’s Breast Oncology Center/X
May 15, 2024, 13:18
Our newest treatment guideline on the use of low-dose Tamoxifen in ER+ DCIS – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared on X:
“Check out our newest treatment guideline on the use of low-dose tamoxifen in patients with estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS).”
Additional information.
Source: Dana-Farber’s Breast Oncology Center/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22